Featured MIMS news

First triple combination MDI licensed for asthma

First triple combination MDI licensed for asthma

Trimbow (beclometasone/formoterol/glycopyrronium) can...

RSS Feed

   

Latest MIMS news

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...

COVID-19 vaccines substantially reduce infection and hospitalisation risk, 'real-world' data shows
Overuse of asthma reliever inhalers ‘a major contributor’ to CO2 emissions in respiratory care
Phyllocontin to be discontinued

Phyllocontin to be discontinued

Phyllocontin Continus 225mg and Phyllocontin Forte...

Stay alert to postpartum bleeding risk with antidepressants, MHRA warns

Stay alert to postpartum bleeding risk with antidepressants, MHRA warns

Observational data suggest that the use of SSRIs and...

Join a MIMS Learning webinar on dermatology for skin of colour

Join a MIMS Learning webinar on dermatology for skin of colour

In this free live webinar for dermatologists, specialist...

Majority of COVID-19 vaccine side-effects 'mild and short lasting', MHRA analysis confirms

Majority of COVID-19 vaccine side-effects 'mild and short lasting', MHRA analysis confirms

Most adverse reactions reported for the Pfizer/BioNTech...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Twice-weekly news bulletin
Alert: Urgent prescribing updates Clinics: Disease-themed monthly round-up

Sign me up

This site is intended for healthcare professionals.